![]() ![]() Importantly, for tissue-based research projects using the future VTR, researchers will be required to deposit results from SEER-linked VTR studies in a data sharing platform. Pathology departments and/or laboratories providing requested services (eg, sharing tissue, whole slide imaging, pathologist review, etc) will be able to recoup costs incurred directly through the SEER registries. The NCI will provide funding for personnel and technologic infrastructure, and researchers using this resource will pay a fee for services rendered by and through the registries. It is anticipated that 2 funding sources will be available for the future scaled VTR. The SEER registries will function as honest brokers to supply deidentified but linked tissue and data. Researchers will be able to apply to access a searchable, web-based interface to select cancer cases ascertained within geographic areas covered by participating registries. The NCI’s Surveillance Research Program, which oversees the SEER registries, is currently investigating the feasibility of a Virtual Tissue Repository (VTR) to establish an infrastructure for acquisition of deidentified clinical data, tissue resources, and whole slide images for cancer research at the population level. ![]() The Surveillance, Epidemiology, and End Results (SEER) cancer registry system, sponsored by the National Cancer Institute (NCI), is a unique data resource that routinely collects data on all incident cancer cases, including long-term follow-up information. 2– 4 One alternative source of tissue from cancer patients is archival formalin-fixed, paraffin-embedded (FFPE) tissue, routinely collected in clinical practice for diagnostic purposes. Additionally, such investigator-initiated and pharmaceutical company–sponsored studies are not necessarily representative of the US population. 1 Not only is the procedure for acquiring fresh tumor specimens costly and not always feasible, but researchers collecting such tissue specimens do not always have access to clinical records and long-term follow-up information. With the rise of personalized medicine for cancer treatment, there is an increasing demand to profile molecular features of tumors. Surveillance Research Program, Division of Cancer Control and Population Sciences (Yuan, Van Dyke, Petkov, Hussey, Penberthy), and the Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis (Moravec), National Cancer Institute, National Institutes of Health, Rockville, Maryland the HIV/AIDS Program, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (Altekruse) the Cancer Registry of Greater California, Department of Public Health, Sacramento (Sandoval, Cress) the Connecticut Tumor Registry, State Department of Public Health, Hartford (Mueller) the Hawaii Tumor Registry, University of Hawaii Cancer Center, Honolulu (Mogi, Hernandez) the Iowa Cancer Registry, The University of Iowa, Iowa City (Selk, Lynch) the Kentucky Cancer Registry, University of Kentucky, Markey Cancer Center, Lexington (Tucker) the Louisiana Tumor Registry, Louisiana State University School of Public Health, New Orleans (Lynch, Lefante, Wu) and the Utah Cancer Registry (Sweeney, Doherty) and Huntsman Cancer Institute (Doherty), University of Utah, Salt Lake City. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |